

An Influence of Endometrial Hyperplasia Regarding Pathos Physiology, Diagnosis, Differential Diagnosis, Treatment, Complications and Consultations
Abstract
Endometrial hyperplasia is a uterine pathology in which morphological changes happen in the cells of the endometrium and exemplifies a precursor to the most common gynecologic malignancy in developed countries, endometrial cancer. It is most commonly caused by increased estrogen exposure and a relative lack of progesterone, which is known as "unopposed estrogen." Because risk factors are increasing at the same time as obesity, diabetes, or other linked conditions, the condition's incidence is increasing. In order to successfully stop the development of endometrial cancer, doctors need to be aware of the symptoms of endometrial hyperplasia, especially if they are treating patients who also have obesity and polycystic ovarian disease. Healthcare practitioners will graduate from this course with a thorough understanding of the etiology, diagnosis, and treatment of endometrial hyperplasia. In addition to examining the most recent developments in diagnostic methods, therapeutic approaches, and preventative measures, the importance of an interprofessional care team in early diagnosis and referral for suitable intervention is emphasized. This exercise highlights the value of assisting patients in making decisions about their fertility objectives and surgical risk factors, as well as facilitating early intervention. By gaining the knowledge and abilities required to properly diagnose, assess, and treat patients with endometrial hyperplasia, participants can ultimately slow the spread of endometrial cancer and improve patient outcomes and care quality.
References
Contreras, N. A., Sabadell, J., Verdaguer, P., Julià, C., & Fernández-Montolí, M. E. (2022). Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients: Current evidence and future directions. International Journal of Molecular Sciences, 23(5), Article 2856. https://doi.org/10.3390/ijms23052856
Nees, L. K., Heublein, S., Steinmacher, S., Juhasz-Böss, I., Brucker, S., Tempfer, C. B., & Wallwiener, M. (2022). Endometrial hyperplasia as a risk factor for endometrial cancer. Archives of Gynecology and Obstetrics, 306(2), 407-421. https://doi.org/10.1007/s00404-022-06711-7
Sanderson, P. A., Critchley, H. O., Williams, A. R., Arends, M. J., & Saunders, P. T. (2017). New concepts for an old problem: The diagnosis of endometrial hyperplasia. Human Reproduction Update, 23(2), 232-254. https://doi.org/10.1093/humupd/dmw051
Shen, Y., Yang, W., Liu, J., & Zhang, Y. (2023). Minimally invasive approaches for the early detection of endometrial cancer. Molecular Cancer, 22(1), Article 53. https://doi.org/10.1186/s12943-023-01843-w
Lathigara, D., Kaushal, D., & Wilson, R. B. (2023). Molecular mechanisms of western diet-induced obesity and obesity-related carcinogenesis: A narrative review. Metabolites, 13(5), Article 686. https://doi.org/10.3390/metabo13050686
Chittenden, B. G., Fullerton, G., Maheshwari, A., & Bhattacharya, S. (2009). Polycystic ovary syndrome and the risk of gynecological cancer: A systematic review. Reproductive BioMedicine Online, 19(3), 398-405. https://doi.org/10.1016/j.rbmo.2009.05.010
Schumer, S. T., & Cannistra, S. A. (2003). Granulosa cell tumor of the ovary. Journal of Clinical Oncology, 21(6), 1180-1189. https://doi.org/10.1200/JCO.2003.04.076
Lee, M., Piao, J., & Jeon, M. J. (2020). Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with tamoxifen. Yonsei Medical Journal, 61(4), 317-322. https://doi.org/10.3349/ymj.2020.61.4.317
Lancaster, J. M., Powell, C. B., Chen, L. M., Richardson, D. L., & Society of Gynecologic Oncology Clinical Practice Committee. (2015). Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 136(1), 3-7. https://doi.org/10.1016/j.ygyno.2014.10.034
Ryan, N. A. J., McMahon, R., Tobi, S., Snowsill, T., Esquibel, S., Wallace, A. J., Bunstone, S., Bowers, N., Mosneag, I. E., Kitson, S. J., O'Flynn, H., Ramchander, N. C., Sivalingam, V. N., Frayling, I. M., Bolton, J., McVey, R. J., Evans, D. G., & Crosbie, E. J. (2020). The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLOS Medicine, 17(9), Article e1003263. https://doi.org/10.1371/journal.pmed.1003263
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33. https://doi.org/10.3322/caac.21708
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17-48. https://doi.org/10.3322/caac.21798
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016). Endometrial cancer. The Lancet, 387(10023), 1094-1108. https://doi.org/10.1016/S0140-6736(15)00130-0
Kurman, R. J., & Norris, H. J. (1982). Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer, 49(12), 2547-2559. https://doi.org/10.1002/1097-0142(19820615)49:12<2547::AID-CNCR2820491207>3.0.CO;2-K
Gunderson, C. C., Fader, A. N., Carson, K. A., & Bristow, R. E. (2012). Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecologic Oncology, 125(2), 477-482. https://doi.org/10.1016/j.ygyno.2012.03.010
Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., Shen, H., Robertson, A. G., Pashtan, I., Shen, R., Benz, C. C., Yau, C., Laird, P. W., Ding, L., Zhang, W., Mills, G. B., Kucherlapati, R., Mardis, E. R., & Levine, D. A. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), 67-73. https://doi.org/10.1038/nature12113
Trimble, C. L., Kauderer, J., Zaino, R., Silverberg, S., Lim, P. C., Burke, J. J., Alberts, D., Curtin, J. (2006). Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer, 106(4), 812-819. https://doi.org/10.1002/cncr.21780
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021). Endometrial cancer. Nature Reviews Disease Primers, 7(1), Article 88. https://doi.org/10.1038/s41572-021-00346-z
White, K., Potter, J. E., Hopkins, K., Fernández, L., Amastae, J., & Grossman, D. (2012). Contraindications to progestin-only oral contraceptive pills among reproductive-aged women. Contraception, 86(3), 199-203. https://doi.org/10.1016/j.contraception.2012.01.005
Ring, K. L., Mills, A. M., & Modesitt, S. C. (2022). Endometrial hyperplasia. Obstetrics & Gynecology, 140(6), 1061-1075. https://doi.org/10.1097/AOG.0000000000004791.
Refbacks
- There are currently no refbacks.